SHS is primarily supported by public funds from the National Institute of Mental Health, but also has foundation funds from The Brain & Behavior Research Foundation and the Baszucki Family Foundation, and investigator-initiated grants from BrainsWay Ltd and Neuronetics Inc. SHS owns intellectual property involving the use of brain connectivity to target TMS, is a scientific consultant for Magnus Medical, investigator-initiated research funding from Neuronetics and Brainsway, has received speaking fees from Brainsway and Otsuka (for PsychU.org), and is a shareholder in Brainsway (publicly traded) and Magnus Medical (not publicly traded). None of these entities was directly involved in the present work. NB received 2 NARSAD Young Investigator Grants from the Brain & Behavior Research Foundation (NLB: 2018, 2021) and a K01 award K01MH121777 (NLB) that supported the studies this Commentary focuses on.